SMN1 and proximal spinal muscular atrophy: One of the populations most vulnerable to persistent NMJ dysfunction after SMN-dependent treatments are adult SMA patients, as it is likely that some motoneuron loss has already occurred by the time SMN-based treatment is initiated.